Amanote Research
Register
Sign In
Limitations of the Use of Single Base Changes in the P53 Gene to Detect Minimal Residual Disease of Breast Cancer
Molecular Pathology
doi 10.1136/mp.55.3.177
Full Text
Open PDF
Abstract
Available in
full text
Date
June 1, 2002
Authors
R K B Dang
Publisher
BMJ
Related search
Treatment of Minimal Residual Disease in Breast Cancer: A Longitudinal Case Study
Cureus
Minimal Residual Disease
Leukemia Supplements
Minimal Residual Disease
Bone Marrow Transplantation
Transplantation
Hematology
A CD138-independent Strategy to Detect Minimal Residual Disease and Circulating Tumour Cells in Multiple Myeloma
British Journal of Haematology
Hematology
On the Way to Specifically Targeting Minimal Residual Disease?
Breast Cancer Research
Cancer Research
Oncology
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Current Hematologic Malignancy Reports
Cancer Research
Oncology
Hematology
Appropriate Use of Imaging to Detect Primary, Second Primary, and Recurrent Breast Cancer
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Transcriptome and Genome Analysis of Single Disseminated Tumor Cells: Approach to Study Minimal Residual Cancer
Nature Genetics
Genetics
Ethylenediamine Functionalized-Single-Walled Nanotube (F-Swnt)-Assisted in Vitro Delivery of the Oncogene Suppressor P53 Gene to Breast Cancer McF-7 Cells
International Journal of Nanomedicine
Organic Chemistry
Biophysics
Biomaterials
Pharmaceutical Science
Medicine
Bioengineering
Drug Discovery
Nanoscience
Nanotechnology
